MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MEIP
- CUSIP: N/A
- Web: www.meipharma.com
Capitalization:- Market Cap: $98.55 million
- Outstanding Shares: 36,772,000
Average Prices:- 50 Day Moving Avg: $2.84
- 200 Day Moving Avg: $2.01
- 52 Week Range: $1.34 - $3.26
P/E:- Trailing P/E Ratio: 78.82
- Foreward P/E Ratio: -2.18
- P/E Growth: -1370.00
Sales & Book Value:- Annual Revenue: $22.8 million
- Price / Sales: 4.32
- Book Value: $1.49 per share
- Price / Book: 1.80
Profitability:- EBIDTA: $1.06 million
- Return on Equity: 2.57%
- Return on Assets: 2.20%
Debt:- Current Ratio: 11.95%
- Quick Ratio: 11.95%
Misc:- Average Volume: 479,353 shs.
- Beta: 1.56
- Short Ratio: 0.64
Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma, Inc. (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.01. The business earned $4.51 million during the quarter, compared to analyst estimates of $5 million. View MEI Pharma's Earnings History.
Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?
2 analysts have issued 1-year price objectives for MEI Pharma's stock. Their predictions range from $6.50 to $7.00. On average, they anticipate MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.
What are analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (7/20/2017)
- 2. Cann analysts commented, "MEI Pharma and partner Helsinn presented positive findings at the European Hematology Association (EHA) meeting in Madrid, Spain from a genetic mutation analysis of patients in a phase II clinical study of the investigational drug pracinostat and azacitidine in acute myeloid leukemia (AML). These data were previously presented at ASCO in early June 2017. These data support our outlook that Helsinn could launch Pracinostat for the treatment of AML and other potential indications in calendar Q1 2022. Potential sales will be recognized in the form of royalty income by MEI Pharma." (6/26/2017)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Madrigal Pharmaceuticals (MDGL), Kindred Biosciences (KIN), Athersys (ATHX), Zymeworks (ZYME), Faron Pharmaceuticals Oy (FARN), Cascadian Therapeutics (CASC), Aileron Therap (ALRN), Clearside Biomedical (CLSD), Stemline Therapeutics (STML), Kura Oncology (KURA), XBiotech (XBIT), Foamix Pharmaceuticals (FOMX), Spring Bank Pharmaceuticals (SBPH), Arrowhead Pharmaceuticals (ARWR), Ovid Therapeutc (OVID), OncoCyte Corp (OCX), Cempra (CEMP) and Redhill Biopharma (RDHL).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Christine Anna White M.D., Independent Chairman of the Board
- Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
- Brian G. Drazba, Chief Financial Officer, Secretary
- David M. Urso, Senior Vice President of Corporate Development, General Counsel
- Robert D. Mass M.D., Chief Medical Officer
- Charles V. Baltic III, Independent Director
- Kevan E. Clemens Ph.D., Independent Director
- Nicholas R. Glover Ph.D., Independent Director
- Thomas C. Reynolds M.D. Ph.D., Independent Director
- William Dodge Rueckert, Independent Director
Who owns MEI Pharma stock?
MEI Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.01%), InterWest Venture Management Co (1.58%), FMR LLC (0.90%), Wasatch Advisors Inc. (0.69%), OxFORD Asset Management LLP (0.64%) and ClariVest Asset Management LLC (0.55%). View Institutional Ownership Trends for MEI Pharma.
Who sold MEI Pharma stock? Who is selling MEI Pharma stock?
Who bought MEI Pharma stock? Who is buying MEI Pharma stock?
MEI Pharma's stock was purchased by a variety of institutional investors in the last quarter, including ClariVest Asset Management LLC, OxFORD Asset Management LLP, Vanguard Group Inc., JPMorgan Chase & Co., Bank of Montreal Can and Spark Investment Management LLC. View Insider Buying and Selling for MEI Pharma.
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEI Pharma stock can currently be purchased for approximately $2.68.
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for MEI Pharma (NASDAQ:MEIP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $6.75 (151.87% upside) |
Analysts' Ratings History for MEI Pharma (NASDAQ:MEIP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/26/2017 | Cann | Reiterated Rating | Buy | $6.50 | High |  |
| 6/14/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $7.00 | Low | |
| 8/2/2016 | Wedbush | Reiterated Rating | Neutral | $2.00 | N/A | |
| 10/7/2015 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
| 9/2/2015 | Cantor Fitzgerald | Reiterated Rating | Buy | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for MEI Pharma (NASDAQ:MEIP)Earnings History by Quarter for MEI Pharma (NASDAQ MEIP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q3 2017 | ($0.03) | ($0.02) | $5.00 million | $4.51 million | View | N/A | |
| 2/8/2017 | Q217 | ($0.29) | $0.32 | $1.25 million | $17.20 million | View | N/A | |
| 11/8/2016 | Q1 2017 | ($0.14) | ($0.12) | $0.63 million | $1.10 million | View | N/A | |
| 9/6/2016 | Q4 2016 | ($0.20) | ($0.17) | | | View | N/A | |
| 9/2/2015 | Q4 2015 | ($0.23) | ($0.17) | | | View | N/A | |
| 9/9/2014 | Q4 2014 | ($0.37) | ($0.40) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for MEI Pharma (NASDAQ:MEIP)2017 EPS Consensus Estimate: ($0.10)
2018 EPS Consensus Estimate: ($0.57)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q4 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q1 2018 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q2 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q3 2018 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q4 2018 | 1 | ($0.17) | ($0.17) | ($0.17) |
| Q1 2019 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q2 2019 | 1 | ($0.30) | ($0.30) | ($0.30) |
(Data provided by Zacks Investment Research)
Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)Insider Ownership Percentage: 4.62%
Institutional Ownership Percentage: 18.03%
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/9/2015 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 390,572 | $1.84 | $718,652.48 | |
| 1/21/2015 | Charles V Baltic III | Director | Buy | 5,000 | $3.81 | $19,050.00 | |
| 12/9/2014 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 79,085 | $6.01 | $475,300.85 | |
| 12/8/2014 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 9,004 | $6.05 | $54,474.20 | |
| 6/30/2014 | Charles V Baltic III | Director | Buy | 2,000 | $6.56 | $13,120.00 | |
| 10/29/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 299,609 | $8.21 | $2,459,789.89 | |
| 10/2/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 581,646 | $10.16 | $5,909,523.36 | |
| 8/16/2013 | Charles V Baltic III | Director | Buy | 2,600 | $6.82 | $17,732.00 | |
| 6/28/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 7,337 | $7.58 | $55,614.46 | |
| 6/11/2013 | Vivo Ventures V, Llc | Major Shareholder | Sell | 13,727 | $7.80 | $107,070.60 | |
| 5/16/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 17,428 | $9.07 | $158,071.96 | |
| 5/8/2013 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 200,000 | $8.58 | $1,716,000.00 | |
| 1/25/2013 | Charles V Baltic III | Director | Buy | 10,200 | $6.04 | $61,608.00 | |
| 12/21/2012 | Charles V Baltic III | Director | Buy | 3,500 | $7.18 | $25,130.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
| Source: |
|
| Date | Headline |
|---|
 | Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - August 3 at 5:05 AM |
 | Zacks Investment Research Lowers MEI Pharma, Inc. (NASDAQ:MEIP) to Hold
www.americanbankingnews.com - July 23 at 1:19 PM |
| Zacks Investment Research Downgrades MEI Pharma, Inc. (NASDAQ:MEIP) to Hold
www.americanbankingnews.com - July 9 at 11:32 PM |
 | MEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session - Nasdaq
www.nasdaq.com - July 9 at 11:55 AM |
| MEI Pharma, Inc. (MEIP) Receives Buy Rating from Cann
www.americanbankingnews.com - June 26 at 8:34 AM |
| Oppenheimer Holdings, Inc. Analysts Give MEI Pharma, Inc. (MEIP) a $7.00 Price Target
www.americanbankingnews.com - June 15 at 10:46 PM |
 | MEI Pharma (MEIP), Helsinn Group Dose First Patient in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
www.streetinsider.com - June 14 at 9:55 PM |
| Omeros (OMER) Lead Candidate Gets Breakthrough Designation
finance.yahoo.com - June 14 at 9:55 PM |
| MEI Pharma (MEIP), Helsinn Group Dose First Patient in Phase 2 Dose-Optimization Study of Pracinostat and ... - StreetInsider.com
www.streetinsider.com - June 14 at 9:45 AM |
| Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
finance.yahoo.com - June 14 at 9:45 AM |
| Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M - Nasdaq
www.nasdaq.com - June 13 at 8:00 AM |
| MEI Pharma Inc (MEIP) Short Interest Update
www.americanbankingnews.com - June 11 at 12:46 PM |
| Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down - Nasdaq
www.nasdaq.com - June 9 at 11:43 PM |
| Mallinckrodt (MNK) Commences Phase III Study of StrataGraft
finance.yahoo.com - June 8 at 7:27 PM |
| Brokers Set Expectations for MEI Pharma Inc's Q4 2017 Earnings (MEIP)
www.americanbankingnews.com - June 8 at 9:18 AM |
 | Helsinn Group and MEI Pharma Report Correlation between ... - PR Newswire (press release)
www.prnewswire.com - June 7 at 6:08 PM |
 | Helsinn Group and MEI Pharma Report Correlation between ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 9:33 AM |
| Radius (RDUS) Announces Positive Data on Breast Cancer Drug
finance.yahoo.com - June 5 at 7:10 PM |
| MEI Pharma Inc (MEIP) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - June 5 at 4:22 PM |
| Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - June 5 at 9:23 AM |
| MEI Pharma Inc (MEIP) Given a $7.00 Price Target at Oppenheimer Holdings Inc.
www.americanbankingnews.com - June 1 at 11:02 PM |
| Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B
finance.yahoo.com - June 1 at 7:21 PM |
| Today's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma
finance.yahoo.com - June 1 at 9:27 AM |
| MEI Pharma (MEIP) Says Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in CCL and ... - StreetInsider.com
www.streetinsider.com - May 31 at 6:53 PM |
| MEI Pharma (MEIP) Shows Strength: Stock Moves 7.6% Higher
finance.yahoo.com - May 30 at 10:06 AM |
 | Can MEI Pharma Rise Nearly 300%?
247wallst.com - May 26 at 7:18 PM |
| MEI Pharma Inc (MEIP) Coverage Initiated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 25 at 8:51 AM |
| MEI Pharma Inc (MEIP) Now Covered by Analysts at Cann
www.americanbankingnews.com - May 24 at 5:16 PM |
| Catalyst Pharmaceuticals Focuses on Development of Firdapse
finance.yahoo.com - May 23 at 6:00 PM |
| Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher
finance.yahoo.com - May 22 at 10:11 AM |
| MEI Pharma (MEIP), Helsinn Group Announce Upcoming Presentations at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 11:03 AM |
| Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - May 19 at 11:03 AM |
| Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
finance.yahoo.com - May 19 at 11:03 AM |
| Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
finance.yahoo.com - May 17 at 6:28 PM |
| MEI Pharma Inc (MEIP) Raised to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:36 AM |
| MEI Pharma Inc (MEIP) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - May 8 at 7:32 PM |
| MEI Pharma Reports Third Quarter Fiscal Year 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 5 at 8:44 AM |
| MEI Pharma Reports Third Quarter Fiscal Year 2017 Results
finance.yahoo.com - May 4 at 11:44 AM |
| Positive Press Coverage Extremely Likely to Affect MEI Pharma (MEIP) Share Price
www.americanbankingnews.com - April 29 at 11:58 AM |
| MEI Pharma (MEIP) Receiving Very Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 8:00 AM |
 | MEI Pharma (MEIP) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 11:10 AM |
| 8:02 am MEI Pharma announces appointment of Brian Drazba as CFO
finance.yahoo.com - April 4 at 8:48 AM |
| MEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 8:48 AM |
| MEI Pharma to Present at Needham Healthcare Conference
finance.yahoo.com - March 28 at 10:29 AM |
| MEI Pharma (MEIP) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 6:37 PM |
| MEI Pharma to Present at Oppenheimer Healthcare Conference
finance.yahoo.com - March 14 at 11:09 AM |
| MEI PHARMA, INC. Financials
finance.yahoo.com - February 11 at 6:36 PM |
 | MEI Pharma Reports Second Quarter Fiscal Year 2017 Results
www.bizjournals.com - February 8 at 7:18 PM |
| MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 8 at 7:18 PM |
MEI Pharma (MEIP) Chart for Sunday, August, 20, 2017
